Skip to main content
MedVellum
QuestionsVideosPricing

MedVellum

Fellowship exam preparation across every specialty: source-verified topics, questions in every format, and videos.

Product

  • Specialties
  • Questions
  • Videos
  • Exam tools
  • Pricing

Verification & policy

  • Verified register
  • Editorial policy
  • Privacy
  • Terms

Account

  • Sign in
  • Create account
  • Dashboard
  • Account & billing

© 2026 MedVellum. For education only — not a substitute for clinical judgement.

llms.txtPsychiatry LLM catalogSitemap

Psych MEQs / SAQsPsychopharmacology — renal and hepatic disease

Psych MEQs / SAQs · Psychopharmacology — renal and hepatic disease

Psychotropics in CKD and cirrhosis (MEQ)

FRANZCP-style MEQ on lithium in falling eGFR, depression in CKD/cirrhosis, BZD–HE risk, and EXTRIP.

20 marks20 min2 min readVerification in progress

Target exams

FRANZCPMRCPsychABPNMD-DNB
On this page
Study tools

Target exams

FRANZCPMRCPsychABPNMD-DNB
Prompt
A 62-year-old man with bipolar I disorder has been stable for 8 years on lithium carbonate (current 12-hour trough 0.72 mmol/L). eGFR has fallen from 78 to 48 mL/min/1.73 m² over 4 years. He also has Child–Pugh B cirrhosis from prior alcohol use (now abstinent 2 years), takes ramipril and intermittent ibuprofen for knee pain, and has new major depression with passive death wishes. (i) Interpret the lithium–renal trajectory and immediate drug-interaction risks. (ii) Outline investigations and monitoring adjustments. (iii) Discuss antidepressant choices in light of CAST/ERBP evidence and his dual organ impairment. (iv) Explain benzodiazepine policy for insomnia given cirrhosis. (v) State when EXTRIP-level care would apply if he presented with lithium toxicity. (20 marks)

Model answer

Reveal model answerShowHide

(i) Lithium–renal trajectory and interactions. Progressive eGFR decline on long-term lithium requires shared nephrology–psychiatry interpretation: distinguish chronic lithium-related concentrating defects/nephropathy risk from other CKD drivers, without panic-stopping a uniquely effective anti-manic and anti-suicide agent without a plan. Immediate risks: ACE inhibitor (ramipril) and intermittent NSAID (ibuprofen) raise lithium levels via reduced clearance — stop casual NSAIDs, counsel sick-day rules, consider analgesic alternatives, and recheck a 12-hour trough promptly after any intercurrent illness or drug change.[4][5][8]

(ii) Investigations and monitoring. U&E/eGFR, 12-hour lithium trough, TFT, calcium, LFT/albumin/INR (cirrhosis staging), FBC, ECG if indicated, MSE and suicide risk review. Increase frequency of lithium levels and renal panels given eGFR 48 and interacting drugs; document target band (often lower in older/impaired clearance) using AGNP-style TDM discipline.[5][8][9]

(iii) Antidepressants. ERBP synthesis: antidepressant PK and sparse efficacy data in CKD 3–5 are agent-specific. CAST: sertraline not superior to placebo for MDD symptoms in non-dialysis CKD, more GI adverse effects — use for shared decision, not nihilism. Prefer lower-start SSRI with favourable renal PK teaching (e.g. sertraline 25–50 mg oral daily titrated) plus psychotherapy access; avoid agents with heavy renal metabolite burden or high hepatic DILI risk where alternatives exist; monitor sodium and bleeding risk. Cirrhosis adds free-fraction and sedation caution.[1][2][3][10]

(iv) Benzodiazepines. Avoid casual BZD for insomnia in Child–Pugh B cirrhosis; Grønbæk links new BZD use to first-time HE risk in cirrhosis with ascites physiology. Prefer sleep hygiene, treat HE drivers, and if a BZD is unavoidable use low-dose LOT teaching (lorazepam/oxazepam/temazepam) short-term only with asterixis/sedation monitoring — not chronic diazepam stacks.[7][10]

(v) EXTRIP. If toxicity (coarse tremor, ataxia, confusion, seizures) with impaired kidney function and high concentration, or severe neurological/cardiac features: stop lithium, IV isotonic saline if depleted, serial levels; extracorporeal treatment recommended per EXTRIP (HD preferred; watch redistribution rebound). Charcoal does not bind lithium.[6][8]

Psychiatry Fellowship Pro

Continue reading

You have read the opening of this meqs / saq. The complete unit — every section and its primary-source references — is part of the Psychiatry Fellowship fellowship library.

Sign in to continueSee pricing
References10ShowHide
  1. [1]Baghdady NT, Banik S, Swartz SA, et al. Psychotropic drugs and renal failure: translating the evidence for clinical practice Adv Ther, 2009.PMID 19444657
  2. [2]Nagler EV, Webster AC, Vanholder R, et al. Antidepressants for depression in stage 3-5 chronic kidney disease: a systematic review of pharmacokinetics, efficacy and safety with recommendations by European Renal Best Practice (ERBP) Nephrol Dial Transplant, 2012.PMID 22859791
  3. [3]Hedayati SS, Gregg LP, Carmody T, et al. Effect of Sertraline on Depressive Symptoms in Patients With Chronic Kidney Disease Without Dialysis Dependence: The CAST Randomized Clinical Trial JAMA, 2017.PMID 29101402
  4. [4]McKnight RF, Adida M, Budge K, et al. Lithium toxicity profile: a systematic review and meta-analysis Lancet, 2012.PMID 22265699
  5. [5]Shine B, McKnight RF, Leaver L, et al. Long-term effects of lithium on renal, thyroid, and parathyroid function: a retrospective analysis of laboratory data Lancet, 2015.PMID 26003379
  6. [6]Decker BS, Goldfarb DS, Dargan PI, et al. Extracorporeal Treatment for Lithium Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup Clin J Am Soc Nephrol, 2015.PMID 25583292
  7. [7]Grønbæk L, Watson H, Vilstrup H, et al. Benzodiazepines and risk for hepatic encephalopathy in patients with cirrhosis and ascites United European Gastroenterol J, 2018.PMID 29774154
  8. [8]Gitlin M Lithium side effects and toxicity: prevalence and management strategies Int J Bipolar Disord, 2016.PMID 27900734
  9. [9]Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017 Pharmacopsychiatry, 2018.PMID 29390205
  10. [10]Telles-Correia D, Barbosa A, Cortez-Pinto H, et al. Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity World J Gastrointest Pharmacol Ther, 2017.PMID 28217372
Psychiatry Fellowship Pro

$29/ monthor $279 / year

The complete Psychiatry Fellowship library, every exam format, one subscription.

  • Complete library for one chosen specialty
  • Timed MCQ mock exams and spaced review
  • Clinical cases & cross-table vivas
See pricingSign in
PreviousPsychotic disorder due to another medical condition — assessment to management (MEQ)General adult psychiatry — secondary / organic psychosisNextPsychotropics, sedation and driving (MEQ)Psychopharmacology — fitness to drive